ArticleComprehensive Physiology2026
Phenotyping of Fontan-Associated Renal Physiology and Disease.
Article in Comprehensive Physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacokinetics in the Fontan circulation: a multi-organ puzzle.European heart journal. Cardiovascular pharmacotherapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKidney dysfunction is prevalent but insufficiently understood in Fontan patients. We aimed to investigate Fontan-Associated Renal Disease (FARD) through comprehensive phenotyping using biomarkers of renal function and injury, as well as ultrasound assessment of intrarenal hemodynamics.
methodsWe prospectively collected data on serum creatinine and cystatin C levels, and 24-h urine creatinine clearance and albumin excretion in 25 Fontan patients, comparing them to healthy age- and sex-matched controls. Additionally, we measured intrarenal venous and arterial flow patterns using Doppler ultrasonography.
resultsMedian age was 28 (Q1-Q3: 19-35) years, with 48% female. Compared to controls, Fontan patients had similar creatinine-based eGFR (eGFR
conclusionFARD involves a progressive decline in kidney function and glomerular injury. eGFR
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.